After a couple of pipeline setbacks, Celgene has said it is preparing to file five new products between now and the end of 2020 that analysts say will reduce its reliance on cancer cash-cow Revlimid.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,